Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
Intravenous immunoglobulin (IVIG) preparations are increasingly being used in the treatment of autoimmune disorders. This treatment is regarded as generally safe, and most of the adverse effects associated with IVIG administration are mild and transient. This paper reports a 72-year-old patient with known ischemic heart disease admitted for a Guillain-Barré syndrome variant, who developed acute ST elevation myocardial infarction (MI) during the first hours of IVIG infusion. The literature on acute MI during IVIG treatment is reviewed. Evaluation of each patient for cardiovascular risk prior to IVIG treatment is recommended as is the assessment of risk versus benefit. If IVIG is prescribed, we propose close monitoring and slow infusion rate.
Barsheshet
Alon
A
Heart Institute, Sheba Medical Center, and Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Marai
Ibrahim
I
Appel
Shmulik
S
Zimlichman
Eyal
E
D000208:Acute Disease; D000368:Aged; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D007167:Immunotherapy; D007262:Infusions, Intravenous; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced*
D016756:Immunoglobulins, Intravenous